Literature DB >> 24188490

Role of matrix metalloproteinases in animal models of ischemic stroke.

Sébastien Lenglet1, Fabrizio Montecucco, François Mach.   

Abstract

Matrix metalloproteinases (MMP) comprise a family of at least 25 zinc-dependent endopeptidases that play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after stroke, the dysregulation of MMPs has been described to increase acute neurovascular disruption and cerebral injury. In particular, MMP-mediated alterations lead to blood-brain barrier (BBB) leakage, cerebral edema, hemorrhage, leukocyte infiltration and progressive inflammatory reactions underlying brain tissue loss. In addition, MMPs have been also shown to play critical activities during the repair phases of cerebral ischemia, particularly during angiogenesis and reestablishment of cerebral blood flow. The aim of this narrative review is to elucidate the mechanisms by which MMPs may provide detrimental and/or beneficial effects during the post-stroke injury and repair phases in animal models.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24188490     DOI: 10.2174/15701611113116660161

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  15 in total

Review 1.  The influence of the amyloid ß-protein and its precursor in modulating cerebral hemostasis.

Authors:  William E Van Nostrand
Journal:  Biochim Biophys Acta       Date:  2015-10-27

Review 2.  Advances in intervention methods and brain protection mechanisms of in situ and remote ischemic postconditioning.

Authors:  Jian-Hui Guo; Li-Yan Li; Chun-Yan Li; Wei Ma; Kuang-Pin Liu; Jin-Wei Yang; Xian-Bin Wang; Zhen Wu; Tong Zhang; Jia-Wei Wang; Wei Liu; Jie Liu; Yu Liang; Xing-Kui Zhang; Jun-Jun Li
Journal:  Metab Brain Dis       Date:  2020-10-12       Impact factor: 3.584

Review 3.  Matrix metalloproteinases as therapeutic targets for stroke.

Authors:  Yi Yang; Gary A Rosenberg
Journal:  Brain Res       Date:  2015-04-25       Impact factor: 3.252

4.  Sphingomyelin Synthase 1 Regulates Neuro-2a Cell Proliferation and Cell Cycle Progression Through Modulation of p27 Expression and Akt Signaling.

Authors:  Umadevi V Wesley; James F Hatcher; Robert J Dempsey
Journal:  Mol Neurobiol       Date:  2014-08-02       Impact factor: 5.590

Review 5.  Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation.

Authors:  Sonia Villapol
Journal:  Cell Mol Neurobiol       Date:  2017-10-03       Impact factor: 5.046

6.  Levistolide A Attenuates Alzheimer's Pathology Through Activation of the PPARγ Pathway.

Authors:  Xiaodan Qu; Peipei Guan; Li Han; Zhanyou Wang; Xueshi Huang
Journal:  Neurotherapeutics       Date:  2020-10-09       Impact factor: 7.620

7.  Early VEGF inhibition attenuates blood-brain barrier disruption in ischemic rat brains by regulating the expression of MMPs.

Authors:  Hai-Tao Zhang; Ping Zhang; Yi Gao; Chen-Long Li; Hong-Jun Wang; Ling-Chao Chen; Yan Feng; Rui-Yan Li; Yong-Li Li; Chuan-Lu Jiang
Journal:  Mol Med Rep       Date:  2016-11-29       Impact factor: 2.952

Review 8.  Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer's Disease.

Authors:  Manoj Govindarajulu; Priyanka D Pinky; Jenna Bloemer; Nila Ghanei; Vishnu Suppiramaniam; Rajesh Amin
Journal:  PPAR Res       Date:  2018-10-21       Impact factor: 4.964

9.  Increased matrix metalloproteinases expression in tuberous sclerosis complex: modulation by microRNA 146a and 147b in vitro.

Authors:  D W M Broekaart; J van Scheppingen; J J Anink; L Wierts; B van Het Hof; F E Jansen; W G Spliet; P C van Rijen; W W Kamphuis; H E de Vries; E Aronica; E A van Vliet
Journal:  Neuropathol Appl Neurobiol       Date:  2019-07-01       Impact factor: 8.090

Review 10.  Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke.

Authors:  Renée J Turner; Frank R Sharp
Journal:  Front Cell Neurosci       Date:  2016-03-04       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.